Pharmaceuticals 2010, 3(8), 2387-2397; doi:10.3390/ph3082387
Article

Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders

Renaud David 1,* email, Emmanuel Mulin 1 email, Patrick Mallea 2 email and Philippe H. Robert 1,2 email
1 Centre Mémoire de Ressources et de Recherche/Hôpital de Cimiez, 4 av Reine Victoria, 06000 Nice, France 2 Centre d’Innovation et d’Usage en Santé (CIU-S) / Hôpital de Cimiez, 4 av Reine Victoria, 06000 Nice, France
* Author to whom correspondence should be addressed.
Received: 2 June 2010; in revised form: 21 June 2010 / Accepted: 20 July 2010 / Published: 26 July 2010
(This article belongs to the Special Issue Alzheimer's Disease Drugs)
PDF Full-text Download PDF Full-Text [182 KB, uploaded 26 July 2010 15:37 CEST]
Abstract: Behavioral and psychological symptoms (BPSD) are now known to be frequently associated to cognitive and functional decline in Alzheimer‘s disease and related disorders. They are present since the early stages of the disease and have negative impact on the disease process. BPSD assessment is crucial in clinical practice and also in future clinical trials targeting disease-modifying therapies for dementia. In this article, we will first review current assessment tools for BPSD, mainly global and domain-specific scales, and new assessment methods, currently available or in development, including new scales, diagnostic criteria and new technologies such as ambulatory actigraphy.
Keywords: neuropsychiatric symptoms; assessment tools; Alzheimer’s disease; clinical trials; actigraphy

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

David, R.; Mulin, E.; Mallea, P.; Robert, P.H. Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders. Pharmaceuticals 2010, 3, 2387-2397.

AMA Style

David R, Mulin E, Mallea P, Robert PH. Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders. Pharmaceuticals. 2010; 3(8):2387-2397.

Chicago/Turabian Style

David, Renaud; Mulin, Emmanuel; Mallea, Patrick; Robert, Philippe H. 2010. "Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders." Pharmaceuticals 3, no. 8: 2387-2397.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert